Car driving on road from above
NEWS FROM ALNYLAM

Here you can find the latest press releases from Alnylam.

Download PDF ›
PRESS RELEASE
April 4, 2024
Alnylam Receives Positive Reimbursement Recommendation From The Canadian Agencies For Drugs And Technology In Health (CADTH) For AMVUTTRA®
Download PDF ›
PRESS RELEASE
May 18, 2022
Alnylam launches third RNAi therapeutic approved in Canada
Download PDF ›
PRESS RELEASE
March 17, 2021
Alnylam Wins Prestigious Prix Galien Canada Award for Best Innovative Product with First-Ever Health Canada-Approved RNAi Therapeutic, ONPATTRO® (patisiran)
Download PDF ›
PRESS RELEASE
July 23, 2019
Alnylam launches the first ever RNAi therapeutic approved in Canada
Download PDF ›
PRESS RELEASE
May 15, 2019
Harnessing RNAi: Alnylam Pharmaceuticals is conquering rare diseases one drug at a time
Download PDF ›
PRESS RELEASE
November 26, 2018
Alnylam Pharmaceuticals: Bringing groundbreaking gene silencing therapies to Ontario.
Download PDF ›
PRESS RELEASE
September 24, 2018
Alnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy

GET IN TOUCH

Questions, concerns, or comments about this content? We encourage you to reach out to our team.

Contact us ›

OTHER INQUIRIES

Media: media@alnylam.com

Investor Relations: investors@alnylam.com

General: info@alnylam.ca